Format

Send to

Choose Destination
Virology. 2016 Dec;499:121-135. doi: 10.1016/j.virol.2016.09.012. Epub 2016 Sep 19.

Mood stabilizers inhibit cytomegalovirus infection.

Author information

1
Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, 06510 New Haven, CT, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, 333 Cedar Street, 06510 New Haven, CT, USA; School of Medicine and Surgery, Ph.D. Program in Neuroscience, University of Milan-Bicocca, via Cadore 48, 20900 Monza, Italy; Department of Obstetrics and Gynecology, Foundation MBBM, University of Milan-Bicocca, via Pergolesi 33, 20900 Monza, Italy.
2
Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, 06510 New Haven, CT, USA.
3
Department of Pediatrics, Yale University School of Medicine, 333 Cedar Street, 06510 New Haven, CT, USA.
4
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, 333 Cedar Street, 06510 New Haven, CT, USA.
5
Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, 06510 New Haven, CT, USA. Electronic address: anthony.vandenpol@yale.edu.

Abstract

Cytomegalovirus (CMV) infection can generate debilitating disease in immunocompromised individuals and neonates. It is also the most common infectious cause of congenital birth defects in infected fetuses. Available anti-CMV drugs are partially effective but are limited by some toxicity, potential viral resistance, and are not recommended for fetal exposure. Valproate, valpromide, and valnoctamide have been used for many years to treat epilepsy and mood disorders. We report for the first time that, in contrast to the virus-enhancing actions of valproate, structurally related valpromide and valnoctamide evoke a substantial and specific inhibition of mouse and human CMV in vitro. In vivo, both drugs safely attenuate mouse CMV, improving survival, body weight, and developmental maturation of infected newborns. The compounds appear to act by a novel mechanism that interferes with CMV attachment to the cell. Our work provides a novel potential direction for CMV therapeutics through repositioning of agents already approved for use in psychiatric disorders.

KEYWORDS:

Cytomegalovirus; Development; Mood stabilizers; Perinatal infection

PMID:
27657833
PMCID:
PMC5102808
DOI:
10.1016/j.virol.2016.09.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center